Product Data Sheet

Tenatoprazole

Cat. No.: HY-17421 CAS No.: 113712-98-4 Molecular Formula: $C_{16}H_{18}N_4O_3S$ Molecular Weight: 346.4

Target: Proton Pump

Pathway: Membrane Transporter/Ion Channel

Storage: Powder -20°C 3 years

2 years

-80°C In solvent 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (144.34 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8868 mL	14.4342 mL	28.8684 mL
	5 mM	0.5774 mL	2.8868 mL	5.7737 mL
	10 mM	0.2887 mL	1.4434 mL	2.8868 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (7.22 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H $^+$ /K $^+$ -ATPase activity with an IC $_{50}$ of 6.2 μ M. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV $^{[1][2][3]}$.
In Vitro	Tenatoprazole (TU-199) (0.1, 0.2, 0.4 mg/kg; oral; single; Heidenhain-pouch dogs) dose-dependently suppresses gastric acid

Tenatoprazole (TU-199) (0.1, 0.2, 0.4 mg/kg; oral; single; Heidenhain-pouch dogs) dose-dependently suppresses gastric acid secretion stimulated by histamine infusion^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Thomson AB, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23(8):1179-1187.
- [2]. Uchiyama K, et al. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol. 1999;21(2):115-122.
- [3]. Mannemuddhu SS, et al. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency. J Virol. 2021;95(13):e0246620.
- [4]. Uchiyama K, et al. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol. 1999;51(4):457-464.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA